In this issue:
CARTITUDE-4: Cilta-cel beats standard of care in RRMM
Myeloma contamination in autografts is a negative prognostic biomarker
iSTOPMM: SMM prevalence in Iceland
Functional genomics approach identifies novel myeloma targets
IKEMA shows durable PFS benefit to isatuximab combo
POLARIS: first-in-human evaluation of GPRC5D-directed CAR T-cell therapy
High antitumour activity of GPRC5D CAR T cells in RRMM
TGA registrations
Exercise may bolster immunity in patients with MM
Significant financial burden of myeloma
IMMagine-1 clinical trial paused by FDA
Evolution of myeloma from precursor conditions
COVID-19 resources
Conferences & Workshops
Please login below to download this issue (PDF)